Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
I was thinking about a program to solve Sudoku.You fill a 9x9 grid with numbers from 1 to 9. The same number must not be ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...
Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Elon Musk spent the early hours of October 15 teasing what sounds like Tesla's next major AI unveiling, telling followers ...
AI improves itself and creates even better AI.Such technology is attracting attention as a realistic research topic. It is ...
4don MSN
Superintelligence may never arrive, Deutsche Bank says. What that could mean for the US economy.
Deutsche Bank’s Jim Reid said he sees productivity gains from artificial-intelligence adoption as having the potential to ...
Ethereum ( ETH -0.45%) co-founder Vitalik Buterin is proposing an intriguing new vision for Ethereum, saying in an essay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results